Myelodysplastic syndromes in the elderly (Q34139758)

31 July 2017

1 reference

title

Myelodysplastic syndromes in the elderly. (English)

1 reference

31 July 2017

Saba HI

1

1 reference

31 July 2017

language of work or name

1 reference

1 January 2001

1 reference

31 July 2017

1 reference

31 July 2017

volume

8

1 reference

31 July 2017

issue

1

1 reference

31 July 2017

page(s)

79-102

1 reference

Proposals for the classification of the myelodysplastic syndromes

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800112

World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800112

The non-random distribution of point mutations in leukaemia and myelodysplasia--a possible pointer to their aetiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800112

RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800112

Correlation of N-ras point mutations with specific chromosomal abnormalities in primary myelodysplastic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800112

Utility of the FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800112

Prognostic factors in the myelodysplastic syndromes: importance of initial data on peripheral blood counts, bone marrow cytology, trephine biopsy and chromosomal analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800112

Modifications in the classification of primary myelodysplastic syndromes: the addition of a scoring system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800112

Danazol therapy in myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800112

Differentiation of myeloid leukaemic cells: new possibilities for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800112

Response of preleukemic syndromes to continuous infusion of low-dose cytarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800112

The myelodysplastic syndromes: current approaches to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800112

Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800112

A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800112

High-dose cytosine arabinoside in the treatment of preleukemic disorders: a leukemia intergroup study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800112

Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800112

The role of intensive chemotherapy in myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800112

MDR1 gene expression and treatment outcome in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800112

Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin A

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800112

The myelodysplastic syndromes: biology and implications for management

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800112

Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800112

Phase II study of recombinant human granulocyte-macrophage colony-stimulating factor in myelodysplastic syndrome and aplastic anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800112

Differential dose-related haematological effects of GM-CSF in pancytopenia: evidence supporting the advantage of low- over high-dose administration in selected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800112

Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. A phase I-II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800112

Hematologic and cytogenetic findings in myelodysplastic syndromes treated with recombinant human granulocyte colony-stimulating factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800112

A phase II trial of recombinant human granulocyte colony-stimulating factor in the myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800112

Effects of prolonged treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800112

Interleukin-2 therapy for myelodysplastic syndrome: does it work?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800112

Recombinant human interleukin-8 restores function in neutrophils from patients with myelodysplastic syndromes without stimulating myeloid progenitor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800112

Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800112

Thrombopoietin and interleukin 11 have different modulatory effects on cell cycle and programmed cell death in primary acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800112

A randomized trial of 13-cis retinoic acid with or without cytosine arabinoside in patients with the myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800112

A randomized phase-I/II multicenter study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia. EORTC Leukemia Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480100800112

10.1177/107327480100800112

21 January 2018

Identifiers

DOI

0 references

1 reference